Patents by Inventor William John Trigg
William John Trigg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9951011Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: GrantFiled: September 19, 2014Date of Patent: April 24, 2018Assignee: GE HEALTHCARE LIMITEDInventors: William John Trigg, Paul Alexander Jones
-
Patent number: 9481685Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: GrantFiled: October 2, 2009Date of Patent: November 1, 2016Assignee: GE Healthcare LimitedInventors: Harry John Wadsworth, Bo Shan, Dennis O'Shea, Joanna Marie Passmore, William John Trigg
-
Publication number: 20160222024Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: ApplicationFiled: September 19, 2014Publication date: August 4, 2016Inventors: William John Trigg, Paul Alexander Jones
-
Publication number: 20160214936Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: ApplicationFiled: September 19, 2014Publication date: July 28, 2016Inventors: William John TRIGG, Paul Alexander JONES
-
Patent number: 8865125Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using.Type: GrantFiled: August 20, 2010Date of Patent: October 21, 2014Assignee: GE Healthcare LimitedInventors: Michelle Avory, William John Trigg
-
Patent number: 8790619Abstract: An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent.Type: GrantFiled: March 26, 2010Date of Patent: July 29, 2014Assignee: GE Healthcare LimitedInventors: Harry John Wadsworth, Bo Shan, Dennis O'Shea, Joanna Marie Passmore, William John Trigg, Amanda Ewan
-
Patent number: 8501153Abstract: The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of said precursor compound and said PET tracer. Also provided by the present invention is a radiopharmaceutical composition comprising the PET tracer of the invention. Methods for using the PET tracer and the radiopharmaceutical composition are also provided.Type: GrantFiled: September 13, 2010Date of Patent: August 6, 2013Assignee: GE Healthcare LimitedInventors: Radha Achanath, Srinath Balaji, Afsal M. Kadavilpparampu Mohamed, Umamaheshwar Mokkapati, Steven Fairway, Dimitrios Mantzilas, Dennis O'Shea, William John Trigg, Harry John Wadsworth, Joanna Marie Passmore, Bo Shan
-
Publication number: 20120189547Abstract: The present invention provides radiofluorinated compounds useful for in vivo imaging GABAA receptors. Also provided by the present invention is a method of synthesis for the radiofluorinated compounds of the invention, in particular an automated method of synthesis. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention.Type: ApplicationFiled: October 8, 2010Publication date: July 26, 2012Inventors: John Woodcraft, Clare L. Jones, Alessandra Gaeta, William John Trigg, Paul Alexander Jones, Stuart Plant
-
Patent number: 8198298Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: February 14, 2011Date of Patent: June 12, 2012Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Publication number: 20120134923Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using.Type: ApplicationFiled: August 20, 2010Publication date: May 31, 2012Inventors: Michelle Avory, William John Trigg
-
Patent number: 8106069Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: April 23, 2010Date of Patent: January 31, 2012Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Francesco Angelucci, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Publication number: 20120020884Abstract: An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent.Type: ApplicationFiled: March 26, 2010Publication date: January 26, 2012Inventors: Harry John Wadsworth, Bo Shan, Dennis O'shea, Joanna Marie Passmore, William John Trigg, Amanda Ewan
-
Publication number: 20120003154Abstract: The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.Type: ApplicationFiled: March 19, 2010Publication date: January 5, 2012Inventors: Harry John Wadsworth, William John Trigg
-
Publication number: 20110190618Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: ApplicationFiled: October 2, 2009Publication date: August 4, 2011Inventors: Harry John Wadsworth, Bo Shan, Dennis O' Shea, Joanna Marie Passmore, William John Trigg
-
Publication number: 20110136857Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: ApplicationFiled: February 14, 2011Publication date: June 9, 2011Applicant: PFIZER ITALIA S.R.L.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Publication number: 20110070161Abstract: The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of said precursor compound and said PET tracer. Also provided by the present invention is a radiopharmaceutical composition comprising the PET tracer of the invention. Methods for using the PET tracer and the radiopharmaceutical composition are also provided.Type: ApplicationFiled: September 13, 2010Publication date: March 24, 2011Applicant: GE HEALTHCARE LIMITEDInventors: RADHA ACHANATH, SRINATH BALAJI, STEVEN FAIRWAY, AFSAL M. KADAVILPPARAMPU MOHAMED, DIMITRIOS MANTZILAS, UMAMAHESHWAR MOKKAPATI, DENNIS O'SHEA, JOANNA MARIE PASSMORE, BO SHAN, WILLIAM JOHN TRIGG, HARRY JOHN WADSWORTH
-
Patent number: 7888508Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: December 23, 2004Date of Patent: February 15, 2011Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Publication number: 20100210476Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: ApplicationFiled: April 23, 2010Publication date: August 19, 2010Applicant: PFIZER ITALIA S.R.L.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Francesco Angelucci, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Patent number: 7728140Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: December 23, 2004Date of Patent: June 1, 2010Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Francesco Angelucci, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard